Subtitle 2c—Prescription Drug Affordability Board

• MD Health Gen T. 21, Subt. 2c, Refs & Annos
• § 21–2c–01. Definitions
• § 21–2c–02. Established;  Purpose
• § 21–2c–03. Membership
• § 21–2c–03. Membership
• § 21–2c–03. Membership
• § 21–2c–03. Membership
• § 21–2c–03. Membership
• § 21–2c–04. Prescription Drug Affordability Stakeholder Council
• § 21–2c–05. Disclosure of Conflict of Interest
• § 21–2c–06. Acceptance of Gifts or Donations
• § 21–2c–07. Study of Aspects of Pharmaceutical Distribution and Payment;  Report
• § 21–2c–07. Study of Aspects of Pharmaceutical Distribution and Payment;  Report
• § 21–2c–08. Identifying Prescription Drug Products that Create Affordability Challenges for State Health Care System and Patients
• § 21–2c–08. Identifying Prescription Drug Products that Create Affordability Challenges for State Health Care System and Patients
• § 21–2c–09. Cost Review of Prescription Drug Products Identified in § 21–2c–08
• § 21–2c–10. Trade Secrets;  Confidential and Proprietary Information
• § 21–2c–11. Funding Source for Board
• § 21–2c–11. Annual Fee;  Prescription Drug Affordability Fund
• § 21–2c–11. Annual Fee;  Prescription Drug Affordability Fund
• § 21–2c–12. Enforcement of Subtitle
• § 21–2c–13. Setting Upper Payment Limits for Prescription Drug Products
• § 21–2c–13. Setting Upper Payment Limits for Prescription Drug Products
• § 21–2c–13. Setting Upper Payment Limits for Prescription Drug Products
• § 21–2c–13. Setting Upper Payment Limits for Prescription Drug Products
• § 21–2c–13. Process for Setting Upper Payment Limits for Prescription Drug Products that Lead to Affordability Challenges
• § 21–2c–14. Appeal of Board Decision
• § 21–2c–14. Setting Upper Payment Limits for Prescription Drug Products
• § 21–2c–14. Upper Payment Limits
• § 21–2c–15. Report;  Contents
• § 21–2c–15. Appeal of Board Decision
• § 21–2c–15. Appeals
• § 21–2c–16. Report;  Contents
• § 21–2c–16. Report